WDR3 (WD repeat domain 3) is a nuclear protein containing 10 WD repeat modules that functions as a component of the small subunit (SSU) processome, the first precursor of the small eukaryotic ribosomal subunit 1. During ribosomal biogenesis, WDR3 participates in RNA folding, modifications, rearrangements, and cleavage of pre-rRNA within the nucleolus. Beyond its ribosomal function, WDR3 operates in multiple cellular pathways including signal transduction, cell cycle progression, and gene regulation 1. WDR3 exhibits oncogenic properties across several malignancies. In prostate cancer, WDR3 overexpression promotes stem cell-like properties by ubiquitinating and degrading USF2, thereby inhibiting RASSF1A transcription 2. In pancreatic cancer, WDR3 activates the Hippo signaling pathway through GATA4 interaction, promoting YAP1 expression and tumor progression 3. WDR3 undergoes liquid-liquid phase separation (LLPS) in osteosarcoma, and its phase separation mediates Nilotinib therapeutic response 4. WDR3 was identified as a core gene in colorectal cancer networks 5, and WDR3 variants show association with thyroid cancer risk 6. Additionally, WDR3 variants exhibit sex-specific association with schizophrenia in females 7. These findings suggest WDR3 represents a potential therapeutic target across multiple cancer types and psychiatric conditions.